ITGR

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the medical devices & supplies - specialty industry, including Integer Holdings (NYSE:ITGR) and its peers. The medical devices industry operates a business model that balances steady demand with significant investments in innovation and regulatory compliance. The industry benefits from recurring revenue streams tied to consumables, maintenance services, and incremental upgrades to the latest technologies, although specialty devices are more niche. The capital-intensive nature of product development, coupled with lengthy regulatory pathways and the need for clinical validation, can weigh on profitability and timelines. In addition, there are constant pricing pressures from healthcare systems and insurers maximizing cost efficiency. Over the next several years, one tailwind is demographic–aging populations means rising chronic disease rates that drive greater demand for medical interventions and monitoring solutions. Advances in digital health, such as remote patient monitoring and smart devices, are also expected to unlock new demand by shortening upgrade cycles. On the other hand, the industry faces headwinds from pricing and reimbursement pressures as healthcare providers increasingly adopt value-based care models. Additionally, the integration of cybersecurity for connected devices adds further risk and complexity for device manufacturers. The 7 medical devices & supplies - specialty stocks we track reported a strong Q1. As a group, revenues beat analysts’ consensus estimates by 5.3%. Thankfully, share prices of the companies have been resilient as they are up 7.4% on average since the latest earnings results. With its name reflecting the mathematical term for "whole" or "complete," Integer Holdings (NYSE:ITGR) is a medical device outsource manufacturer that produces components and systems for cardiac, vascular, neurological, and other medical applications. Integer Holdings reported revenues of $439.6 million, flat year on year. This print exceeded analysts’ expectations by 3.1%. Despite the top-line beat, it was still a slower quarter for the company with a significant miss of analysts’ full-year EPS and revenue guidance. “First quarter financial performance was in line with our outlook and primarily reflected the previously communicated head...

PLANO, Texas, July 02, 2026 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), a leading global medical device contract development and manufacturing organization (CDMO), announced today that it will webcast its conference call to discuss financial results and business highlights for the second quarter ended July 3, 2026, on Thursday, Aug. 6, 2026, at 8 a.m. CT (9 a.m. ET). Other forward-looking and material information may also be discussed during the call. The company will issue a news release announcing its financial results for the second quarter on Aug. 6, 2026 prior to the conference call. Conference call details: Date: Thursday, Aug. 6, 2026 Time: 8 a.m. CT (9 a.m. ET) Domestic dial-in number: 800-715-9871 International dial-in number: 646-307-1963 Conference ID: 3120125 Webcast Registration: ITGR Q2 2026 Earnings Call An audio replay will be available for seven days and can be accessed by dialing 800-770-2030 or 609- 800-9909 and using Conference ID 3120125. The conference call will also be available live and via archived replay on the Investor Relations section of the Integer website at: investor.integer.net. From time to time, Integer posts information that may be of interest to investors on its website. To automatically receive Integer financial news by email, please visit investor.integer.net and subscribe to email alerts. Learn more about Integer at www.integer.net. About Integer®Integer Holdings Corporation (NYSE: ITGR) is one of the largest medical device contract development and manufacturing organizations (CDMOs) in the world, serving the cardio and vascular, neuromodulation, and cardiac rhythm management markets. As a strategic partner of choice, we advance the goals of our medical device customers through industry-leading engineering and manufacturing, with a relentless commitment to quality, service, and innovation. The Company's brands include Greatbatch Medical® and Lake Region Medical®. Additional information is available at www.integer.net. ContactsMedia Relations:Misty [email protected] Investor Relations:Kristen [email protected]

It has been about a month since the last earnings report for Integra LifeSciences (IART). Shares have added about 15% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Integra due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its latest earnings report in order to get a better handle on the important catalysts. Integra LifeSciences Holdings Corporation (IART) delivered adjusted earnings per share (EPS) of 54 cents for the first quarter of 2026, which beat the Zacks Consensus Estimate by 32.8%. The metric increased 31.7% year over year. GAAP loss per share was 6 cents in the quarter compared with the year-ago period’s loss of 33 cents. Total revenues in the first quarter rose 2.4% year over year to $391.9 million. The metric topped the Zacks Consensus Estimate by 2.7%. Organically, revenues rose 1.3% year over year. For full-year 2026, the company expects revenues to be in the range of $1.66-$1.70 billion, representing reported growth of 1.6% to 4.1%. The Zacks Consensus Estimate is pegged at $1.67 billion, indicating 2.2% year-over-year growth. Meanwhile, the company updated its expected adjusted EPS to a range of $2.40-$2.50. The Zacks Consensus Estimate for the metric is pegged at $2.42 per share. For the second quarter of 2026, Integra expects reported revenues in the range of $410-$425 million. The Zacks Consensus Estimate is pegged at $417.5 million. Adjusted EPS is expected to be in the range of 44-52 cents. The Zacks Consensus Estimate for the metric is pegged at 49 cents per share. In the past month, investors have witnessed a downward trend in estimates review. The consensus estimate has shifted -10.74% due to these changes. Currently, Integra has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with an F. However, the stock has a grade of B on the value side, putting it in the top 40% for value investors. Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in. Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Interestingly, Integra has a Zacks Rank #2 (Buy). We expect an above average return from the stock i...

Integer Holdings has had an impressive run over the past six months as its shares have beaten the S&P 500 by 15%. The stock now trades at $85.04, marking a 25% gain. This performance may have investors wondering how to approach the situation. Is there a buying opportunity in Integer Holdings, or does it present a risk to your portfolio? Dive into our full research report to see our analyst team’s opinion, it’s free. Despite the momentum, we're swiping left on Integer Holdings for now. Here are three reasons why ITGR doesn't excite us and a stock we'd rather own. Larger companies benefit from economies of scale, where fixed costs like infrastructure, technology, and administration are spread over a higher volume of goods or services, reducing the cost per unit. Scale can also lead to bargaining power with suppliers, greater brand recognition, and more investment firepower. A virtuous cycle can ensue if a scaled company plays its cards right. With just $1.86 billion in revenue over the past 12 months, Integer Holdings is a small company in an industry where scale matters. This makes it difficult to build trust with customers because healthcare is heavily regulated, complex, and resource-intensive. Forecasted revenues by Wall Street analysts signal a company’s potential. Predictions may not always be accurate, but accelerating growth typically boosts valuation multiples and stock prices while slowing growth does the opposite. Over the next 12 months, sell-side analysts expect Integer Holdings’s revenue to stall, a deceleration versus its 12.4% annualized growth for the past five years. This projection doesn't excite us and indicates its products and services will see some demand headwinds. Growth gives us insight into a company’s long-term potential, but how capital-efficient was that growth? Enter ROIC, a metric showing how much operating profit a company generates relative to the money it has raised (debt and equity). Integer Holdings historically did a mediocre job investing in profitable growth initiatives. Its five-year average ROIC was 5.4%, somewhat low compared to the best healthcare companies that consistently pump out 20%+. Integer Holdings’s business quality ultimately falls short of our standards. With its shares topping the market in recent months, the stock trades at 13.3× forward P/E (or $85.04 per share). While this valuation is reasonable, we d...

By Suzanne McGee and Isla Binnie PROVIDENCE, Rhode Island, May 15 (Reuters) - Private credit pioneer Ares Management disclosed ‌a wide array of new or increased stakes ‌in alternative asset vehicles including several direct lending funds in its quarterly 13-F filing with the U.S. Securities and Exchange Commission on Friday. Ares, an alternative asset manager that said this month it raised a record $30 billion during the first quarter, revealed that ‌it initiated a ⁠position in medical device manufacturer Integer Holdings during the same period, a stake that was ⁠valued at $53.3 million as of March 31. It also made smaller first-time investments in business development companies (BDCs) BlackRock TCP Capital and Carlyle Secured Lending. The asset manager boosted 17 other holdings, including in ‌several other BDCs, which raise equity and pair it with leverage to lend to small and mid-sized companies. The asset class has come under pressure due to doubts about lending standards and concerns that artificial intelligence will disrupt the ‌software businesses to which many of these BDCs had extended loans. Ares increased its holdings in Golub Capital BDC and Blue Owl ‌Technology Finance. It added to its position in its own BDC, Ares Capital Corp. In contrast, Ares's only sale was the liquidation of its stake in New Mountain Finance. ‌The latter sold a portfolio of $477 million in assets in February. (Reporting by Suzanne McGee in Providence, Rhode Island; Editing by Sanjeev Miglani)

Integer reported Q1 results roughly in line with prior guidance but lowered full‑year guidance, now forecasting reported sales of $1.805–$1.835 billion and adjusted EPS of $5.83–$6.40 with organic sales expected flat to down ~1%. The board has initiated a strategic review amid intensified interest in the company, though management says there is no timeline and no assurance the review will result in a transaction. Management highlighted margin pressure from lower fixed‑cost absorption and electrophysiology (PFA) forecast volatility, is implementing additional near‑term cost actions, and has continued share repurchases (~$100M completed) with net leverage at 3.2x. Interested in Integer Holdings Corporation? Here are five stocks we like better. After blowout earnings, Integer may be headed to new highs Integer (NYSE:ITGR) reported first-quarter 2026 results that management said were in line with the outlook it provided in February, while also lowering its full-year forecast to reflect updated customer forecasts and additional risk adjustments across its portfolio. The company also disclosed that its board has initiated a strategic review process. President and CEO Payman Khales said first-quarter sales rose 0.5% year over year on a reported basis and increased 1.3% organically. Khales attributed the quarter’s sales performance primarily to “the decline associated with the three new products” previously discussed by the company, along with the impact of exiting the Portable Medical business. → Corning Beats Q1 Estimates but Drops 9% on Guidance Miss Diron Smith, executive vice president and CFO, said first-quarter sales totaled $440 million. The company posted adjusted EBITDA of $85 million, down $7 million, and adjusted operating margin contracted 230 basis points to 13.9%. Adjusted net income was $41 million, down 10% year over year, and adjusted EPS was $1.20, down 8%. Khales said adjusted EPS benefited from lower interest expense, which was offset by the decline in adjusted operating income. Smith added that interest expense was $4 million lower than the prior year, contributing $0.10 per share, reflecting savings from a convertible debt offering completed in March 2025. → Meta Posted Its Best Sales Growth Since 2021—So Why Did Shares Fall? Smith said Cardio & Vascular (C&V) sales increased 1% to $262 million in the quarter, “which primarily reflected lower...

Performance in Q1 was primarily impacted by the previously identified decline in three specific products and the strategic exit from the portable medical market. Management attributes the updated 2026 outlook to recent customer forecast reductions in the electrophysiology (EP) market, which they characterize as a period of 'normalization' following rapid Pulsed Field Ablation (PFA) adoption. The EP forecast adjustments are described as short-term inventory and production plan recalibrations by OEMs rather than a loss of market share, in-sourcing, or shifts to competitors. Beyond specific EP updates, management has applied broader risk adjustments across the entire portfolio to minimize the impact of potential further forecast erosion during this volatile period. Operating margin contraction of 230 basis points in Q1 was driven by lower fixed cost absorption resulting from the lower sales volume. Management emphasizes that 2026 is a transition year, with the underlying medical device markets remaining strong and the company's long-term strategy unchanged. The company expects to return to organic sales growth at 200 basis points above the market rate in 2027, supported by a robust new product introduction (NPI) pipeline. Guidance for the remainder of 2026 assumes organic sales will return to market growth levels by the fourth quarter, despite a 5% headwind from fewer production days. Management is implementing additional near-term cost reduction actions to mitigate bottom-line pressure without compromising the ability to service 2027 growth commitments. The 2027 growth algorithm assumes the EP market will stabilize in the mid-to-high teens growth range, with Integer's portfolio contributing significantly to above-market performance. Capital expenditure is projected to remain at 5% to 6% of sales to support long-term growth initiatives and high-growth markets like structural heart and neurovascular. The Board of Directors has initiated a formal strategic review to evaluate opportunities to maximize shareholder value, citing 'heightened interest' in the company in recent months. Management clarified that the strategic review has no definitive timeline and may result in continuing the current stand-alone strategy. The exit from the portable medical business is now complete, contributing to a 1% inorganic decline in the 2026 reported sales outlook. The company com...

Integer Holdings Corporation ITGR delivered adjusted earnings per share (EPS) of $1.20 in the first quarter of 2026, which declined 8.4% year over year. The figure missed the Zacks Consensus Estimate by 0.8%. The adjustments include expenses related to the amortization of intangible assets and restructuring and restructuring-related charges, among others. GAAP EPS for the quarter was 48 cents, up 172.7% from the prior-year quarter. Integer Holdings registered revenues of $439.6 million in the first quarter, up 0.5% year over year. The figure topped the Zacks Consensus Estimate by 3%. Organically, revenues increased 1.3%. Robust sales from the majority of the product lines drove the company’s top line in the reported period. Integer Holdings operates through three product lines — Cardio and Vascular (C&V); Cardiac Rhythm Management & Neuromodulation (CRM&N) and Other Markets. During the fourth quarter of 2025, management began referring to ITGR’s Advanced Surgical, Orthopedics & Portable Medical product line as the Other Markets product line. This was aimed at better capturing the evolving nature of the company’s products and ongoing strategic focus. Per management, the name change has no impact on the financial information previously reported. In the first quarter of 2026, the C&V segment generated revenues of $262 million, reflecting a modest 1% year-over-year increase. Growth in the segment was primarily supported by continued strength in neurovascular and contributions from prior acquisitions. However, performance was partially offset by lower electrophysiology sales, mainly related to previously disclosed headwinds from certain new products. The CRM&N segment reported revenues of $168 million, up 5% year over year. Growth was driven by solid performance in the cardiac rhythm management business, which more than offset ongoing weakness in neuromodulation. The neuromodulation decline was consistent with prior expectations and reflects previously communicated product-related headwinds. Revenues from Other Markets declined year over year, primarily due to the continued impact of Integer Holdings’ strategic exit from the Portable Medical business. This segment remains outside the company’s core growth focus and largely reflects legacy manufacturing service agreements tied to divested operations. Integer Holdings Corporation price-consensus-eps-surprise-chart...

Integer (ITGR) came out with quarterly earnings of $1.2 per share, missing the Zacks Consensus Estimate of $1.21 per share. This compares to earnings of $1.31 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -0.66%. A quarter ago, it was expected that this medical device outsource manufacturer would post earnings of $1.7 per share when it actually produced earnings of $1.76, delivering a surprise of +3.53%. Over the last four quarters, the company has surpassed consensus EPS estimates two times. Integer, which belongs to the Zacks Medical - Instruments industry, posted revenues of $439.58 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 3.04%. This compares to year-ago revenues of $437.39 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Integer shares have added about 6.7% since the beginning of the year versus the S&P 500's gain of 4.2%. While Integer has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Integer was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong...

~ First quarter results in line with February outlook ~ ~ Updates 2026 outlook ranges; continues to expect 200bps above-market organic sales growth in 2027 ~ PLANO, Texas, April 30, 2026 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR) today announced results for the three months ended April 3, 2026. First Quarter 2026 Highlights (compared to First Quarter 2025, except as noted) Sales increased 0.5% to $440 million, with organic growth of 1.3%. GAAP operating income from continuing operations decreased $18 million to $32 million, a decrease of 36%. Non-GAAP adjusted operating income decreased $10 million to $61 million, a decrease of 14%. GAAP income from continuing operations increased $39 million to $17 million, an increase of 173%. Non-GAAP adjusted net income decreased $5 million to $41 million, a decrease of 10%. GAAP diluted EPS income from continuing operations increased $1.14 to $0.48, an increase of 173%. Non-GAAP adjusted EPS decreased $0.11 to $1.20, a decrease of 8%. Adjusted EBITDA decreased $6 million to $85 million, a decrease of 7%. From the end of 2025, total debt increased $66 million to $1.252 billion and Non-GAAP net total debt increased $74 million to $1.264 billion, resulting in a leverage ratio of 3.2 times adjusted EBITDA as of April 3, 2026. “First quarter financial performance was in line with our outlook and primarily reflected the previously communicated headwinds associated with the three new products,” said Payman Khales, Integer’s President and CEO. “Given recent customer forecast updates and market dynamics, we believe it was prudent to further risk adjust our outlook. We remain focused on executing our strategy, navigating the temporary headwinds, and building momentum during the second half of 2026. We expect to return to 200 basis points above-market organic sales growth in 2027.” Discussion of Product Line First Quarter 2026 Sales Cardio & Vascular sales increased 1% to $262 million in the first quarter 2026 compared to the first quarter 2025, reflecting the previously communicated headwinds associated with the two new products in Electrophysiology. Cardiac Rhythm Management & Neuromodulation sales increased 5% to $168 million in the first quarter 2026 compared to the first quarter 2025. Cardiac Rhythm Management growth was partially offset by the previously communicated headwind in Neuromodulation. Other Marke...

PLANO, Texas (AP) — PLANO, Texas (AP) — Integer Holdings Corp. (ITGR) on Thursday reported first-quarter earnings of $16.5 million. On a per-share basis, the Plano, Texas-based company said it had net income of 48 cents. Earnings, adjusted for amortization costs and non-recurring costs, were $1.20 per share. The results fell short of Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for earnings of $1.21 per share. The medical device outsource manufacturer posted revenue of $439.6 million in the period, which topped Street forecasts. Five analysts surveyed by Zacks expected $426.6 million. Integer expects full-year earnings in the range of $5.83 to $6.40 per share, with revenue in the range of $1.81 billion to $1.84 billion. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ITGR at https://www.zacks.com/ap/ITGR

For the quarter ended March 2026, Integer (ITGR) reported revenue of $439.58 million, up 0.5% over the same period last year. EPS came in at $1.20, compared to $1.31 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $426.6 million, representing a surprise of +3.04%. The company delivered an EPS surprise of -0.66%, with the consensus EPS estimate being $1.21. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance. Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance. Here is how Integer performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Sales- Medical Sales- Other Markets: $9.58 million versus $11.17 million estimated by three analysts on average. Sales- Medical Sales- Cardio & Vascular: $261.73 million versus the three-analyst average estimate of $255.39 million. The reported number represents a year-over-year change of +1.1%. Sales- Medical Sales- Cardiac Rhythm Management & Neuromodulation: $168.26 million versus $158.67 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +4.9% change. View all Key Company Metrics for Integer here>>> Shares of Integer have returned -3.2% over the past month versus the Zacks S&P 500 composite's +12.2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research